Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Overview of Lipid Metabolism

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...

Chronic Kidney Disease III: Interprofessional Care

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prevalence of plasma lipid disorders with an emphasis on LDL cholesterol in selected countries in the Asia-Pacific region.

Lipids in health and disease·2021

Same author

Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity.

Nature reviews. Endocrinology·2020

Same author

Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement.

The lancet. Diabetes & endocrinology·2019

Same author

HDL cholesterol and ASCVD risk stratification: A debate.

Atherosclerosis·2019

Same author

Expert opinion on the applicability of dyslipidemia guidelines in Asia and the Middle East.

International journal of general medicine·2018

Same author

Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.

Circulation·2018

Search research articles

Related Experiment Video

Updated: May 7, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Lipoprotein metabolism and CKD: overview.

Philip Barter¹

¹Centre for Vascular Research, University of New South Wales, Sydney, 2052, Australia, pbarter@ozemail.com.au.

Clinical and Experimental Nephrology

|September 21, 2013

Summary

Patients with chronic kidney disease (CKD) exhibit abnormal plasma lipids, including high triglycerides and altered lipoprotein levels. Understanding these changes is crucial for managing cardiovascular risk in CKD patients.

Area of Science:

Nephrology
Cardiovascular Medicine
Lipid Metabolism

Background:

Chronic kidney disease (CKD) is associated with significant alterations in plasma lipid and lipoprotein profiles.
These dyslipidemias contribute to the increased cardiovascular risk observed in CKD patients.

Purpose of the Study:

To provide a comprehensive overview of plasma lipoprotein transport.
To elucidate the specific mechanisms driving lipid and lipoprotein abnormalities in CKD.

Main Methods:

Review of existing literature on lipoprotein metabolism and CKD.
Analysis of common lipid and lipoprotein profiles in CKD patients.

Main Results:

CKD patients often present with hypertriglyceridemia, elevated very low-density lipoproteins (VLDLs), and chylomicrons.

Related Experiment Videos

Last Updated: May 7, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Increased levels of atherogenic VLDL remnants and lipoprotein (a) particles are common.

Reduced concentrations of cardio-protective high-density lipoproteins are frequently observed.

Conclusions:

Lipoprotein abnormalities are a hallmark of chronic kidney disease.
Understanding these mechanisms is key to developing targeted therapies for cardiovascular risk reduction in CKD.